Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies
APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and
suffering of persistent aquagenic pruritus.